Heramed Ltd · ASX:HMD
Heramed — Investor Presentation (October 2020)
25 slides from Heramed's investor presentation, Oct 21, 2020
Slide 1: Leading the digital transformation of maternity care
For personal use only HeraMED ASX:HMD Leading the digital transformation of maternity care October 2020 1
Slide 2: Remote pregnancy care lacks adequate technology
Maternity care Remote pregnancy care has only recently typically requires For personal use only evolved but lacks adequate technology multiple hospital visits > Hospital grade remote foetal heart rate monitoring has not been achievable previously Maturity of Telehealth Programs by Service Line1 > Ba
Slide 3: Mayo Clinic OB Nest Program Positive Clinical Outcomes
Mayo Clinic OB Nest Program Positive Clinical Outcomes1 Proven benefits of 5-year trial program for expecting mothers, resulting in OB Nest becoming the standard of care at Mayo for low- remote Maternity 42% For personal use only risk pregnancies care despite lack of 6 of 14 care visits conducted re
Slide 4: The HeraMED maternity care platform
For personal use only Only clinically validated, Recent trial results FDA clearance for HeraBEAT in clinical The HeraMED maternity care platform confirm hospital grade accuracy of HeraBEAT or home settings1 Solution device Collaboration with Mayo Multiple licensing Value created for all Clinic on ne
Slide 5: HeraMED's end-to-end solution
For personal use only HeraBEAT Maternity Care App HeraCARE Platform HeraMED’s end-to-end solution A hardware & software solution to u n d e r p i n a r e v o l u t i o n i s e d D o c t o r / Pa t i e n t relationship for remote maternity care 5
Slide 6: The HeraBEAT device's unique value proposition
The HeraBEAT devices unique value proposition HeraBEAT Foetal Heart For personal use only ECG Machine ~$10k Rate Monitor CTG Machine Foetal & maternal heart rate monitoring to same accuracy as hospital CTG machines but with Price1 mothers able to operate the device without a trained professional Her
Slide 7: Maternity Companion App
For personal use only Maternity Companion App collates key medical data Foetal heart rate Blood pressure Weight Educational materials Mood Tracking Activity tracking Expectant mothers track & record the foetal heart rate through application 7
Slide 8: Care Manager Dashboard
Care Manager Dashboard For personal use only Monitored by qualified health professionals, digitally integrating a previously analogue process Optimises clinical workflows Enables personalised consultation and support Full access to real-time patient data from Maternity Companion app New business opp
Slide 9: Joondalup Trial Results
Joondalup Trial Results For personal use only 81 100% 96–100% 97% Pregnant Detection of Foetal Percentile for usability Interpretability of Women Heart Rate in all and satisfaction data Clinically “The results of this study show that sessions Interpretable the HeraBEAT device is accurate and easy to
Slide 10: Commercialisation Strategy
For personal use only Commercialisation Strategy 10
Slide 11: Well defined commercialisation strategy
Clinical studies with leading healthcare Well defined providers & key global opinion leaders to gain Commercialisation medical validation & complement existing care For personal use only strategy Mayo Clinic Joondalup Health Campus Acceptance & Customer Satisfaction > Demonstrate patients want to us
Slide 12: Key Collaborations: Mayo Clinic and Joondalup Health Campus
Mayo Clinic Joondalup Health Campus Key Collaborations For personal use only Additional opportunities exist with both existing & new potential Upcoming Trial Clinical Trial partners Clinical study of 60 mothers run measuring: Registered Clinical study complete showing: > Ease of use of HeraBEAT devi
Slide 13: Business Model
Business Model For personal use only HeraMED Enterprise Agreement Healthcare Providers HeraMED & Healthcare Providers Hospitals & Doctors One-time establishment fee Expectant Integrate platform into operations & Mother Per User/Per Month HeraCARE SaaS fee deliver platform to expectant mothers One-ti
Slide 14: Strategic Pathway
Strategic pathway Status Progress Strategic > Built best in class proprietary solution Pathway 1 For personal use only Build Platform Complete > Additional features and updates to be delivered in the near-term > Multiple trials completed > Additional Pilots and Trials in discussion with 1 – 2 2 Pilo
Slide 15: Horizons of Growth
Horizons Horizon 4 of Growth For personal use only Horizon 3 Today Horizon 2 > Achieve reimbursement from insurers Horizon 1 > Undertake trials to test > Commercialise solution monitoring of high-risk > Paid pilots with early patients for monitoring high-risk adopters patients > Confirm sales model
Slide 16: Opportunity Pipeline
Opportunity Potential Partners Number of Births Comment Market Pipeline For personal use only Hospital A 2500 Well progressed USA HMD’s opportunity pipeline is currently focused in Hospital B 3500 Well Progressed AUS Australia and US1 Hospital C 4800 In discussions AUS Hospital D 3,800 Initial Stage
Slide 17: Catalysts
Newsflow Commercial Milestones Catalysts For personal use only Q4 CY20 ✓ Announcement of Joondalup trial results • Expansion of Joondalup study to explore additional applications for the HeraBEAT • 1 – 2 paid pilots commenced • Execution of commercial agreement with eCare21 H1 CY21 • First paid pilo
Slide 18: Executive Summary
For personal use only Executive COVID-19 presents Only medical grade, Multiple licensing opportunity to fast-track clinically validated, agreement discussions Summary adoption of telehealth maternity care platform underway globally First paying customers US$111bn US maternal Value created for all an
Slide 19: Appendix
For personal use only Appendix 19
Slide 20: Distribution Strategy
HeraMED Distribution Strategy For personal use only Direct Distributors Channel Partners Mayo Clinic & Joondalup MedTech Edge eCare21 Health Campus Initial focus is to partner Partnering with distributors Partnering with existing with Industry leaders that That have proven track virtual care platfor
Slide 21: Manufacturing Overview
Manufacturing Overview Crow’s main production facility is located in Afula, in the Northern part of Israel Capability For personal use only 350 employees, 20 engineers and technicians and 6 quality Employees leaders Crows current HeraBEAT manufacturing capacity is +10,000 / per year - ample producti
Slide 22: Board & Management
Dr. Ron Weinberger – Non-Executive Chairman Highly experienced business executive, with strong scientific background and international span, Former Director, President and CEO of Nanosonics Ltd. ASX: NAN, Mkt cap ~$2 Billion, CEO and Managing Director of EMVision Ltd. ASX:EMV, Non- Board & Executive
Slide 23: Share price and shareholders
$0.14 $21.0m $2.3m Share Price Market Cap Cash $0.30 30m For personal use only $0.15 15m $0.00 0m Leading the Oct-19 Dec-19 Feb-20 Apr-20 Jun-20 Aug-20 Volume Share Price digital Shareholder Shares (m) (%) 1 Altshuler Shaham Trusts Ltd <Holley Pharma Co Ltd A/C> 10.9m 7.2% transformation of 2 3 Alts
Slide 24: Disclaimer
Disclaimer Important notice regarding forward looking statements For personal use only This document contains a general summary of the company and is provided for information purposes only. For full details please review HeraMED Limited ACN 626 295 314 (HeraMED) ASX page - https://www.asx.com.au/asx
Slide 25: Contact
For personal use only Contact HeraMED David Groberman, CEO and Co-Founder M: +972 52 699 1188 E: david@hera-med.com Jonathan Hart, Company Secretary M: +61 2 8379 2961 E: jonathan@hera-med.com Alex Radke, General Manager United States M: +1 412 352 9378 E: alex@hera-med.com PAC Partners Tim Chapman,